AI Article Synopsis

  • The study aimed to evaluate oncological outcomes after progressive site-directed therapy (PSDT) in patients with genuine and induced oligometastatic (OM) castration-resistant prostate cancer (CRPC).
  • Among 37 patients analyzed, genuine OM-CRPC showed a significant reduction in PSA levels (95%) after treatment compared to induced OM-CRPC (47%), indicating better efficacy.
  • The findings suggest that genuine OM-CRPC has better outcomes and fewer new metastases during recurrence than induced OM-CRPC, which may indicate a more advanced disease state upon diagnosis.

Article Abstract

Objectives: To describe oncological outcomes after progressive site-directed therapy (PSDT) in genuine and induced oligometasatic (OM)-castration-resistant prostate cancer (CRPC).

Methods: Thirty-seven patients with OM-CRPC treated with PSDT were retrospectively analyzed, and oncological outcomes and recurrence patterns on whole-body diffusion-weighted MRI (WB-DWI) were evaluated.

Results: Twenty-two (59%) were classified as genuine OM-CRPC and 15 (41%) as induced OM-CRPC. A 50% decline in PSA after PSDT was observed in 21 (95%) genuine OM-CRPCs and 7 (47%) induced OM-CRPCs (p = 0.0005). At a median observation period of 7.3 months, median PSA progression-free survival were 10.9 months in the genuine OM-CRPCs and 4.8 months in the induced OM-CRPCs (p = 0.015). Among the patients who developed PSA progression after PSDT, 11 of 15 in the genuine OM-CRPCs (73%) and 11 of 14 in the induced OM-CRPCs (79%) underwent WB-DWI at PSA progression. The median numbers of newly detected metastases were 2 (range: 1-5) in the genuine OM-CRPCs and 4 (range: 1-40) in the induced OM-CRPCs (p = 0.049). Only one new metastasis appeared in 5 patients from the genuine OM-CRPCs (46%) and 1 from the induced OM-CRPCs (9.1%, p = 0.048). In 7 of 9 patients from the genuine OM-CRPCs (78%) and 7 of 8 patients from the induced OM-CRPCs (88%) who had bone metastases alone, the newly detected metastasis limited to the bone.

Conclusions: Genuine OM-CRPC had better oncological outcomes after PSDT than induced OM-CRPC, and the number of lesions detected at recurrence was limited. Induced OM-CRPC might be a disseminated condition with micrometastases at OM diagnosis.

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.15090DOI Listing

Publication Analysis

Top Keywords

genuine om-crpcs
24
induced om-crpcs
24
oncological outcomes
12
induced om-crpc
12
om-crpcs
12
induced
11
genuine
10
genuine induced
8
prostate cancer
8
progressive site-directed
8

Similar Publications

Article Synopsis
  • The study aimed to evaluate oncological outcomes after progressive site-directed therapy (PSDT) in patients with genuine and induced oligometastatic (OM) castration-resistant prostate cancer (CRPC).
  • Among 37 patients analyzed, genuine OM-CRPC showed a significant reduction in PSA levels (95%) after treatment compared to induced OM-CRPC (47%), indicating better efficacy.
  • The findings suggest that genuine OM-CRPC has better outcomes and fewer new metastases during recurrence than induced OM-CRPC, which may indicate a more advanced disease state upon diagnosis.
View Article and Find Full Text PDF

Purpose: To evaluate the clinical characteristics of genuine- and induced-oligometastatic castration-resistant prostate cancer (OM-CRPC) and assess the therapeutic effect of progressive-site directed therapy (PSDT).

Methods: We performed a retrospective analysis of 45 patients with OM-CRPC. Whole-body diffusion-weighted MRI (WB-DWI) was used to diagnose oligo-progressive disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!